Browsing by Author "Frade, P"
Now showing 1 - 9 of 9
Results Per Page
Sort Options
- Clinical efficacy of biosimilar filgrastim in Fernando Fonseca Hospital, PortugalPublication . Fernandes, J; Frade, P; Elias, C; Fonseca, R; Almeida, P
- Devoluções de quimioterapia na unidade de preparação de citotóxicos do Hospital Fernando Fonseca EPEPublication . Fernandes, J; Frade, P; Almeida, P
- A disfunção dopaminérgica mesolímbica na psicose: uma revisão da literaturaPublication . Moura, P; Couto, F; Abreu, M; Vian, J; Moura, T; Frade, P; Levy, PIntrodução: Desde há algumas décadas que se pensa que uma hiperactividade dopaminérgica da via mesolímbica esteja implicada na génese dos sintomas positivos da esquizofrenia. Objectivos: Nesta revisão da literatura procurámos interligar as várias áreas do conhecimento actual, procurando fazer a ponte com a prática clínica. Métodos: Foi efectuada uma pesquisa sistemática da literatura em inglês, até Abril de 2014 através da PUBMED utilizando como termos MeSH (medical subject headings) “mesolimbic” e “psychosis”, tendo-se incluído revisões da literatura. Resultados e Conclusões: Foram encontrados 111 artigos, tendo-se excluído 56 por, após leitura do resumo, se concluir que não estavam relacionados com o tema. Dos restantes 55 foram seleccionados 14 artigos tendo sido mantidas as abreviaturas em inglês para facilitar a sua consulta posterior. São apresentadas evidências sobre o papel desempenhado por vários sistemas reguladores no desenvolvimento dos sintomas positivos associados não apenas a esta doença mas às várias perturbações em que ocorrem, assim como a possível relação entre esses vários factores. Entre os vários sistemas discutidos conta-se a influência do neurodesenvolvimento, da regulação pelos receptores nicotí- nicos da acetilcolina, a influência dos canais de potássio KCNQ, a regulação por péptidos neurotransmissores, pela adenosina e pela fosfodiesterase 10A, assim como avanços na compreensão da etiologia da esquizofrenia. Trata-se, portanto, de um enunciado do substrato neurobiológico dos sintomas positivos.
- Efeitos secundários da hormonoterapia per os em doentes de c. mama do Hospital Fernando FonsecaPublication . Fernandes, J; Martins, N; Frade, P; Oliveira, M; Elias, C; Almeida, P
- Ensaios Clínicos nos Serviços Farmacêuticos do Hospital Prof. Dr. Fernando Fonseca EPEPublication . Fernandes, J; Frade, P; Almeida, P
- Erlotinib in non-small-cell lung cancer patients from Hospital Fernado FonsecaPublication . Fernandes, J; Frade, P; Teixeira, S; Afonso, RINTRODUTION: The oral epidermal growth factor receptor (EGFR) tyrosine-kinase inibitor (TKI) erlotinib is an established second-line treatment for advanced non-small-cell lung cancer (NSCLC).1 Erlotinib delays disease progression and increases survival after first-line chemotherapy in patients with advanced NSCLC as second-line therapy.2 Maintenance therapy with erlotinib, when compared to placebo, could be associated with a significantly longer progression free survival and tolerability mainly in EGFR activating mutation tumours.3 However second line therapy with erlotinib is not more effective than chemotherapy (pemetrexed or other).4,5 In terms of traditional toxicities associated with chemotherapy, Erlotinib seems to have a better safety profile than chemotherapy, with no haematological toxicities, the most common event was mild to moderate skin rash which is relatively manageable.5 There is a lack of evidence regarding efficacy of Erlotinib used as second line versus third line therapy. OBJECTIVES: To compare Erlotinib effectiveness profile in Hospital Fernando Fonseca NSCLC patients when used as second or third line therapy. METHODS: We have followed up 30 NSCLC patients, who have done Erlotinib before and after other approved chemotherapies, during 14 months starting from June 2011. During this period we have collected patient’s demographics and baseline characteristics and also their EGFR mutational status. To determine Erlotinib effectiveness we calculated progression–free survival (PFS) which was defined as the time from Erlotinib therapeutic initiation to the date of documented disease progression or death. RESULTS: The median age of our 30 patients was 62,5 years. The most common pathological subtype was adenocarcinoma (66,7 %). 46,6 % of our patients had received one prior chemotherapy regimen before Erlotinib and 36,6 % had received two prior chemotherapy regimen before Erlotinib. Two patients have done Erlotinib as a first line therapy. Median PFS for second line Erlotinib patients is 18,7 weeks while for third line Erlotinib patients is 12,3 weeks. Only 50 % of our patients had available information regarding EGFR mutational status; however patients who harbor tumor-associated EGFR activating mutation seem to have higher response rates to Erlotinib. Rash was the most common treatment-related adverse event with Erlotinib, as expected. CONCLUSIONS: Our results show that maybe there could be a better disease outcome for advanced NSCLC patients if the oral epidermal growth factor receptor tyrosine-kinase inhibitor (Erlotinib) is administered as a second line therapy instead of using it as a third line therapy. As far EGFR mutational status is concerned it seems that enhanced efficacy is related with EGFR mutation-positive disease. REFERENCES: 1- Summary of product characteristics - Tarceva© 2- Shepherd FA, Pereira J, Ciuleanu T, et al. Erlotinib in previously treated Non-small-cell Lung Cancer. N Eng J Med 2005; 353:123-132. 3- Cappuzzo F, Ciuleanu T, Stelmakh l, et al. Erlotinib as maintaenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study. Lancet Oncol 2010; 11:521-29. 4- Vamvakas L, Agelaki S, Kentepozidis NK, et al. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small-cell lung cancer (NSCLC): results of a randomized phase III Hellenic Oncology Research Group trial. Proc Am Soc Clin Oncol 2010; 28 (suppl): abstr 7519. 5- Ciuleanu T, Stelmakh l, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomized multicentre, open-label, phase 3 study. Lancet Oncol 2012; DOI:10.1016/s1470-2045(11)70395-0
- Identificação e caracterização do doente com VIH/SIDA relativamente ao seu comportamento de adesão à terapêutica anti-retroviral no Hospital Prof. Doutor Fernando Fonseca, EPEPublication . Frade, P; Elias, C; Soares, J; Dória, S; Almeida, P
- Omissões na prescrição da unidade de oncologia sem prescrição electrónica do Hospital Prof. Dr. Fernando Fonseca EPEPublication . Fernandes, J; Frade, P; Teixeira, S
- Oral hormone therapy undesirable effects in breast cancer patients of Fernando Fonseca HospitalPublication . Fernandes, J; Frade, P; Oliveira, MJ; Elias, C; Almeida, P